Related Experiment Videos
Focus on HDL: a new treatment paradigm for athero-thrombotic vascular disease
1Division of Cardiology and Atherosclerosis Research Center, Room 5347, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, California 90048, USA. shahp@cshs.org
Insights
Atherosclerotic vascular disease remains a major health concern. Targeting high-density lipoprotein (HDL) and its component apolipoprotein A-I offers a promising new approach for treating cardiovascular disease.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Pharmacology
Background:
- Atherosclerotic vascular disease is a leading cause of death globally.
- Current treatments improve outcomes but 40-50% of cardiovascular events persist.
- Novel therapeutic targets are needed to address residual risk.
Purpose of the Study:
- To explore apolipoprotein A-I and high-density lipoprotein (HDL) as potential therapeutic targets.
- To investigate HDL-based therapies for atherosclerotic vascular disease.
Main Methods:
- Review of epidemiological studies on HDL-cholesterol and coronary heart disease.
- Analysis of experimental models investigating HDL function.
- Identification of apolipoprotein A-I as a key component of HDL.
Main Results:
- Epidemiological data show a strong inverse correlation between HDL-cholesterol and coronary heart disease.
- Experimental models support a protective role for HDL.
- Apolipoprotein A-I is identified as a primary structural component of HDL.
Conclusions:
- HDL-based therapies represent a potential new strategy for managing atherosclerotic vascular disease.
- Targeting HDL may offer a novel paradigm for prevention and treatment.
- Further research into apolipoprotein A-I and HDL function is warranted.
Abstract:
Atherosclerotic vascular disease is the leading cause of mortality and morbidity in much of the Western world. Although advances in lifestyle and risk factor modification, pharmacotherapy, endovascular interventions and surgery have considerably improved clinical outcome, 40 - 50% of adverse cardiovascular events continue to occur despite current strategies. A number of new targets for therapeutic exploitation are currently being investigated that include, among others, apolipoprotein A-I, the major structural component of high density lipoprotein (HDL) particle. The strong negative relationship between HDL-cholesterol levels and coronary heart disease in epidemiological studies, as well as data from experimental models suggest that HDL-based therapies could be an important new paradigm for prevention, treatment and reversal of atherosclerotic vascular disease.